VistaGen Therapeutics (NASDAQ: VTGN) reported its fiscal year 2026 third‑quarter results, posting a net loss of $0.45 per share and revenue of $303,000. The company’s earnings per share beat the consensus estimate of $-0.51 by $0.06, a surprise of 10.9%, while revenue fell short of the $0.4 million estimate by $0.1 million, a miss of 43.9%.
The EPS beat was driven largely by disciplined cost management amid a heavy investment cycle. R&D expenses rose to $14.2 million, up from $11.3 million in the same quarter last year, but the company maintained tighter operating leverage, allowing it to narrow the loss per share relative to analysts’ expectations. The company’s focus on advancing its PALISADE program for fasedienol and other IND‑enabling projects kept the loss margin within a range that analysts had anticipated.
Revenue declined because the company’s commercial sales remained flat while the clinical‑trial‑related revenue stream was limited to a single phase‑3 trial that generated modest cash receipts. The $0.3 million figure reflects the revenue generated from the PALISADE‑3 trial, which did not meet its primary endpoint and therefore did not generate additional sales. The miss underscores the company’s continued reliance on clinical‑trial revenue rather than product sales.
Comparing to prior periods, VistaGen’s Q3 2025 loss was $14.1 million, or $0.46 per share, and revenue was $0.23 million. The Q2 2026 loss was $19.4 million, indicating a widening loss trend as the company ramps up R&D and G&A spending. The current quarter’s net loss of $18.9 million reflects the cumulative effect of these investments.
Cash and liquidity remain a concern. As of December 31, 2025, VistaGen held $61.2 million in cash, cash equivalents, and marketable securities, a moderate cushion that the company is using to fund its clinical pipeline. R&D and G&A expenses increased to $14.2 million and $5.6 million, respectively, compared to $11.3 million and $4.0 million in the prior year, widening the operating loss.
Management highlighted the company’s strategic focus. CEO Shawn Singh said, "Our mission remains unchanged: to deliver transformative treatments and improve lives." He added, "We have reviewed available data from PALISADE III and implemented moderate refinements." Singh also noted that the IND for refisolone is planned for submission in the first half of 2026 and that the PALISADE‑4 trial may support a potential new drug application for social anxiety disorder. CFO Cindy Anderson emphasized the rise in R&D spending, noting, "Research and development expenses were $11.3 million for the quarter ended December 31, 2024, compared to $4.5 million for the same period last year."
The company faces additional headwinds, including a securities class‑action lawsuit with a lead‑plaintiff deadline of March 16, 2026, and a Nasdaq delisting warning for falling below the $1.00 bid‑price threshold, with a compliance deadline of August 3, 2026. These factors add uncertainty to the company’s near‑term outlook, even as the upcoming PALISADE‑4 topline results and refisolone IND submission could provide new revenue opportunities if successful.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.